New technologies now allow life sciences companies to pursue “outcomes-based” commercial models that directly tie their reimbursements to the real-world outcomes their patients' experience. Those companies that embrace the outcomes-based commercial opportunity early will have the best chance of not only regaining control of key profitability levers, but also influencing the industry’s shift to a healthier financial model.

1. Copyright © 2017 Accenture All rights reserved. Accenture, its logo, and High Performance Delivered are trademarks of Accenture.

2. Copyright © 2017 Accenture All rights reserved. Accenture, its logo, and High Performance Delivered are trademarks of Accenture.
LIFE SCIENCES COMPANIES
HAVE NO TIME TO WASTE
In 2015-2016, United States’
governing bodies proposed
46 distinct bills to legislate
drug pricing.

3. Copyright © 2017 Accenture All rights reserved. Accenture, its logo, and High Performance Delivered are trademarks of Accenture.
THE INDUSTRY FACES A
CRITICAL CHOICE:
Stick with the traditional
commercial model and face
steady economic
compression from regulators
and market forces.
Embrace outcomes-based
care to regain control of
profitability levers and
steer the industry to a
healthier financial model.
OR

4. Copyright © 2017 Accenture All rights reserved. Accenture, its logo, and High Performance Delivered are trademarks of Accenture.
OUTCOMES-BASED CARE DIGITALLY
POWERS BETTER HEALTH MARKETS
New technologies allow life sciences
companies to directly tie reimbursements
to patients’ real-world outcomes.
• Wearables,the Internetof Things,artificial
intelligence,andmobile platforms enable
more targeted, secure, and responsive patient
interventions.
• Predictive real-worldanalytics efficiently
coordinate patients’ care with providers and
relevant services.
• Fair market-value of treatmentsis ensured
via collection, analysis, and application of
patients’ health data.

5. Copyright © 2017 Accenture All rights reserved. Accenture, its logo, and High Performance Delivered are trademarks of Accenture.
OUTCOMES-BASED MODELS
GROWTH OPPORTUNITIES:
Short-Term
• Oncology
• Viral hepatitis
• Diabetes
Future
• Respiratory
• Autoimmune areas

6. Copyright © 2017 Accenture All rights reserved. Accenture, its logo, and High Performance Delivered are trademarks of Accenture.
IT’S TIME TO
PLAY OFFENSE,
NOT DEFENSE
In order to capitalize on the evolving outcomes-based commercial
opportunity, life sciences companies must:
• Increase digital capabilities.Almost all life sciences companies currently lack the
digital tools they need to define, measure, and control patient outcomes.
• Advocate reshapingthe market. Companies must vocally engage regulatory
bodies to reform fair market value, legal frameworks and “best price”
considerations.
• Developa new “outcomes-based” mindset: Health care reinvention requires
constructing an ecosystem of like- minded partners, providers and customers
seeking to drive results-oriented value at every turn.

7. Copyright © 2017 Accenture All rights reserved. Accenture, its logo, and High Performance Delivered are trademarks of Accenture.
A WORLDWIDE HEALTH
REVOLUTION
Falling technology costs will open
up outcomes-based care
opportunities around the world.
First movers will define patients’
health care and industry profitability
for years to come.
Life science companies have no
time to waste.

8. Copyright © 2017 Accenture All rights reserved. Accenture, its logo, and High Performance Delivered are trademarks of Accenture.
Learn more about how outcomes-based models will transform the
future of health care with our full report:
@AccentureStrat
No Time To Waste
JOIN THE CONVERSATION:
@AccentureLifSci
https://www.linkedin.com/company/accenture-strategy
https://www.linkedin.com/showcase/10331490/